5323002025-04-012025-06-305323002025-06-305323002025-04-012025-06-30in-capmkt:OtherExpenses1Member5323002025-04-012025-06-30in-capmkt:OtherExpenses2Member5323002025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323002025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25323002025-06-30Statement15323002025-04-012025-06-30Statement15323002025-06-30StatementDynamic1I1Statement15323002025-06-30StatementDynamic1I2Statement15323002025-06-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532300WOCKPHARMANAINE049B01025Wockhardt LimitedMain BoardEquity2025-04-012026-03-312025-08-082025-08-01INRCroresQuarterlyFirst quarterSingle segmentPharmaceuticals2025-08-0811:35:002025-08-0813:45:00Not applicabletrue1falseNot Applicable as there is no default on loans and the company has no outstanding debt securities as on 30.06.2025.2025-04-012025-06-30UnauditedStandalone41300000002500000004380000000740000000390000000-50000068000000041000000046000000010105000003690000000690000000069000000000006900000000000690000000069000000081000000054.254.25004.254.251)The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 08, 2025. The results have been subjected to limited review by the Statutory Auditors of the Company. <BR> <BR> 2)Figures for the quarter ended March 31, 2025 is the balancing figure between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2024-25. <BR> 3)The Company is exclusively into Pharmaceutical business Segment. <BR> <BR> 4) Other Expenses includes Rounding off amount of 0.05 to keep the totalling in Crores aligned with the PDF file of Financial Results filed alongwith Outcome of the Board Meeting with the Exchange. Other expenses1010000000Rounding off500000Items that will not be reclassified to Profit or Loss - (charge) (consisting of re-measurement of net defined benefit liability)-2300000Rounding off23000000000QIP2024-11-11100000000002025-06-30trueCRISIL RATINGS LIMITEDfalseNANILNILRashmi MamturaCompany Secretary and Compliance OfficerMumbai2025-08-08Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company.No5000000000041631000000Funding in capital expenditure, investment in research and development and incidental expenses.No250000000003277000000General Corporate PurposeNo2239700000227790000013400000000On account of actual issue expenses being lower than estimated as disclosed in the Offer Document, by Rs 3.82 crores and the same has been adjusted with Object 3: General Corporate Purposes